<DOC>
	<DOCNO>NCT02242942</DOCNO>
	<brief_summary>This open-label , multicenter , randomize Phase III study design compare efficacy safety combine regimen obinutuzumab venetoclax versus obinutuzumab + chlorambucil participant chronic lymphocytic leukemia ( CLL ) coexist medical condition . The anticipated time study treatment approximately one year follow-up period 5 year .</brief_summary>
	<brief_title>A Study Compare Efficacy Safety Obinutuzumab + Venetoclax ( GDC-0199 ) Versus Obinutuzumab + Chlorambucil Participants With Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Chlorambucil</mesh_term>
	<criteria>Documented previously untreated CLL accord International Workshop Chronic Lymphocytic Leukemia ( IWCLL ) criteria CLL require treatment accord IWCLL criterion Total Cumulative Illness Rating Scale ( CIRS score ) great ( &gt; ) 6 Adequate marrow function independent growth factor transfusion support within 2 week screen per protocol , unless cytopenia due marrow involvement CLL Adequate liver function Life expectancy &gt; 6 month Agreement use highly effective contraceptive method per protocol Transformation CLL aggressive NonHodgkin 's lymphoma ( Richter 's transformation prolymphocytic leukemia ) Known central nervous system involvement Participants history confirm progressive multifocal leukoencephalopathy ( PML ) An individual organ/ system impairment score 4 assessed CIRS definition limit ability receive treatment regimen trial exception eye , ear , nose , throat organ system Participants uncontrolled autoimmune hemolytic anemia immune thrombocytopenia Inadequate renal function History prior malignancy , except condition list protocol patient recover acute side effect incur result previous therapy Use investigational agent concurrent anticancer treatment within last 4 week registration Participants active bacterial , viral , fungal infection require systemic treatment within last two month prior registration History severe allergic anaphylactic reaction humanize murine monoclonal antibody know sensitivity allergy murine product Hypersensitivity chlorambucil , obinutuzumab , venetoclax excipients Pregnant woman nurse mother Positive test result chronic hepatitis B virus ( HBV ) infection ( define positive hepatitis B surface antigen [ HBsAg ] serology ) positive test result hepatitis C ( hepatitis C virus [ HCV ] antibody serology test ) Participants know infection human immunodeficiency virus ( HIV ) human Tcell leukemia virus1 ( HTLV1 ) Requires use warfarin , marcumar , phenprocoumon Received agent know strong moderate Cytochrome P450 3A inhibitor inducer within 7 day prior first dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>